Evidence map›Paper›PMID 30802699›Full record

ReviewJournal of affective disorders2019

Moving pharmacoepigenetics tools for depression toward clinical use.

Laura M Hack, Gabriel R Fries, Harris A Eyre, Chad A Bousman, Ajeet B Singh, Joao Quevedo, Vineeth P John, Bernhard T Baune, Boadie W Dunlop

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of affective disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. "Novel Psychopharmacology for Depressive Disorders".Advances in experimental medicine and biology · 2021
    Review
  14. Pharmacogenomic testing and antidepressant response: problems and promises.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2020
    Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Laura M HackDepartment of Psychiatry and Behavioral Sciences, School of Medicine, Emory University, Atlanta, GA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Palo Alto, CA 94305, USA; Sierra Pacific Mental Illness Research Education and Clinical Centers, VA Palo Alto Health Care System, Palo Alto, CA, USA. Electronic address: lhack@stanford.edu.
Gabriel R FriesDepartment of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Harris A EyreDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Palo Alto, CA 94305, USA; Innovation Institute, Texas Medical Center, Houston, TX, USA; IMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, Australia; Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
Chad A BousmanDepartments of Medical Genetics, Psychiatry, Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada.
Ajeet B SinghIMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, Australia.
Joao QuevedoDepartment of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Vineeth P JohnDepartment of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Bernhard T BauneDepartment of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
Boadie W DunlopDepartment of Psychiatry and Behavioral Sciences, School of Medicine, Emory University, Atlanta, GA, USA.
The University of Texas Health Science Center at Houston · USEmory University · USDeakin University · AUTexas Medical Center · USThe University of Melbourne · AUUniversity of Calgary · CA

Funding

Emory Psychiatry Clinical Scientist Training Program (CSTP)R25MH101079 · NIMH · EMORY UNIVERSITY · PI GOLDSMITH, DAVID RYAN, MILLER, ANDREW H · 2014 to 2025
$1.9M
NIMH NIH HHS R25 MH101079
6 · The paper itself

Abstract

backgroundMajor depressive disorder (MDD) is a leading cause of disability worldwide, and over half of patients do not achieve symptom remission following an initial antidepressant course. Despite evidence implicating a strong genetic basis for the pathophysiology of MDD, there are no adequately validated biomarkers of treatment response routinely used in clinical practice. Pharmacoepigenetics is an emerging field that has the potential to combine both genetic and environmental information into treatment selection and further the goal of precision psychiatry. However, this field is in its infancy compared to the more established pharmacogenetics approaches.

methodsWe prepared a narrative review using literature searches of studies in English pertaining to pharmacoepigenetics and treatment of depressive disorders conducted in PubMed, Google Scholar, PsychINFO, and Ovid Medicine from inception through January 2019. We reviewed studies of DNA methylation and histone modifications in both humans and animal models of depression.

resultsEmerging evidence from human and animal work suggests a key role for epigenetic marks, including DNA methylation and histone modifications, in the prediction of antidepressant response. The challenges of heterogeneity of patient characteristics and loci studied as well as lack of replication that have impacted the field of pharmacogenetics also pose challenges to the development of pharmacoepigenetic tools. Additionally, given the tissue specific nature of epigenetic marks as well as their susceptibility to change in response to environmental factors and aging, pharmacoepigenetic tools face additional challenges to their development. LIMITATIONS: This is a narrative and not systematic review of the literature on the pharmacoepigenetics of antidepressant response. We highlight key studies pertaining to pharmacoepigenetics and treatment of depressive disorders in humans and depressive-like behaviors in animal models, regardless of sample size or methodology. While we discuss DNA methylation and histone modifications, we do not cover microRNAs, which have been reviewed elsewhere recently.

conclusionsUtilization of genome-wide approaches and reproducible epigenetic assays, careful selection of the tissue assessed, and integration of genetic and clinical information into pharmacoepigenetic tools will improve the likelihood of developing clinically useful tests.

Indexed as

AnimalsAntidepressive AgentsDepressionDNA MethylationEpigenomicsFemaleHumansMajor Depressive DisorderMicroRNAsPharmacogeneticsPrecision MedicineAntidepressive AgentsMicroRNAsAntidepressantsDecision support tools (DSTs)DepressionDNA methylationHistonesPharmacoepigenetics

Identifiers

PMID30802699
PMCPMC6763314
OpenAlexW2914765414

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.